BioWorld

Dec. 14, 2005

Vertex, GSK In Potential $405M VX-409 Preclinical Collaboration

Partnering a promising preclinical pain product, Vertex Pharmaceuticals Inc. granted GlaxoSmithKline plc worldwide development and commercialization rights in a deal worth up to $405 million plus royalties. (BioWorld Today) Read More

Insmed's iPlex: Second Orphan Drug Approved In Short Stature

Missed Phase II Velafermin Endpoint Drops CuraGen

Halozyme's Stock Sale Raising $16.1M After Nod For Hylenex

Other News To Note

ASH Roundup

Today's news in brief

BioWorld

BioWorld briefs for April 2, 2026.

With improved technologies, biomarkers, failed drugs may come into their own

BioWorld

At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...

Comparison of neurons in a healthy brain and nerve cells in neurodegenerative disease with amyloid plaques

Small-molecule TREM2 agonist advances to treat Alzheimer’s

BioWorld Science

Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...

Amlogenyx’s AM-805 reduces amyloid plaques in AD

BioWorld Science

The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 31, 2026